These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Cheema TA; Kanai R; Kim GW; Wakimoto H; Passer B; Rabkin SD; Martuza RL Clin Cancer Res; 2011 Dec; 17(23):7383-93. PubMed ID: 21976549 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
9. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437 [TBL] [Abstract][Full Text] [Related]
10. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks. Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions. Kwon M; Jang H; Kim EH; Roh JL Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740 [TBL] [Abstract][Full Text] [Related]
12. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers. Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948 [TBL] [Abstract][Full Text] [Related]
13. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413 [No Abstract] [Full Text] [Related]
15. Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma. Rasmussen RD; Gajjar MK; Jensen KE; Hamerlik P Mol Oncol; 2016 May; 10(5):751-63. PubMed ID: 26794465 [TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]
17. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726 [TBL] [Abstract][Full Text] [Related]
18. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187 [TBL] [Abstract][Full Text] [Related]